Shots:

• Merck KgaA provides an update on its P-III INTR@PID Lung 037 study and the extensive INTR@PID clinical trial program assessing bintrafusp alfa for patients with BTC and cervical cancer
• Based on the IDMC’s recommendation- Merck will discontinue the INTR@PID Lung 037 study as it fails to meet its co-1EPs- specifically PFS. The ongoing clinical trial INTR@PID Lung 037 includes 1L treatment of patients with stage IV NSCLS having PD-L1 expression
• The company will further evaluate bintrafusp alfa in other studies. GSK has high hopes with the drug as it has paid $4.2B+ in the collaboration signed in 2019

 ­ Ref: Merck KgaA | Image: Merck KgaA